About Us

Our Values

INEX believes that every woman deserves the chance to have the most accurate and up-to-date information to help her take charge of her health

We’re on a mission to help women around the world lead longer, healthier lives.

We started as a small molecular diagnostics company over seven years ago. Today, INEX holds numerous patents and licenses in key areas serving women’s health, including ovarian cancer diagnosis and screening, non-invasive prenatal testing, and same-day prenatal diagnosis.

We take pride in knowing that the technology we offer is making a difference to the lives of women and babies around the world. Everything we do is driven by our brand values:


We strive to remain professional and ethical in all our endeavours, and to treat all our relationships with the utmost of care and respect.


INEX is devoted to developing state-of-the-art technology and making it accessible to women so they have the power to manage their health.


We empower people with our ideas. We impart confidence and motivation, not just within our company, but with everyone we work with, to do great things.


We have the courage and determination to pursue new ideas and new ways of doing things.


We are committed to continuous growth, and to stay ahead of global changes by constantly redefining the high standards we set ourselves.

Our Approach

INEX operates two core business units focused on women’s health and fetal health respectively, and work closely with academic and research institutions to develop new technology.

The National University of Singapore (NUS) provides the base for our research. Technologies such as OvaCIS™, FlashFish™ and Fetal Cells in Maternal Blood have been conceived and researched at the NUS Obstetrics & Gynaecology Research Facility.


Our Leadership

Board of Directors

MD, Ph.D

Prof. Steven Myint is a physician with broad experience at board executive level in academia and the biopharmaceutical sector, with an international reputation in infectious disease research and vaccine development. After his own first university spinout in 1995, he has been involved in the development of over 20 SME’s in life sciences and created over $1billion value for shareholders.

He holds Non-Executive Directorships with several organizations in the public and private sectors. Prof Myint is also a Senior Fellow and Strategic Advisor to A*STAR and on the Board of the Medical School Research Board at National Technological University of Singapore.

Prof Myint is the Founding Partner at Innovatum, as well as formerly Chairman of Green Signal Biopharma. He was a Professor and Dean of Medicine & Health at the University of Survey and Professor of Microbiology & Immunology at the University of Leicester. He has been a Global Medical Director at GlaxoSmithKline and Senior Vice-President for R&D/Chief Medical Officer at BTG International.


Associate Professor Choolani is the principle Founder of INEX. He served as Chairman since the company’s inception in 2006 and was a key driver in the successful development of INEX from a small biotech start-up to a leading women’s health diagnostic company. In February 2014, he continued as Founder Director and manages the strategic and scientific objectives of the company.

A/Professor Choolani leads the High-Risk pregnancy Unit of Maternal-Fetal Medicine Division at the National University Hospital (NUH), where he and his team were instrumental in the development of the breakthrough FlashFISH™ technology. FlashFISH™ is a rapid diagnostic test performed during amniocentesis that can detect Down syndrome in unborn babies within three hours. The technology put Singapore on the world map as being the first country to offer Same-Day Prenatal Diagnosis.

A/Professor Choolani received the Benjamin Henry Sheares’ Memorial Lecture Award in 2010 for his outstanding work in Obstetrics and Gynaecology. He has also been awarded the National Medical Research Council (NMRC) Clinician Scientist award for his outstanding contribution to research.

A/Professor Choolani has published over 100 articles and abstracts in notable journals and currently chairs the National University of Singapore’s Leadership in Academic Medicine Clinician Scientist Unit and the National Healthcare Group’s Clinician Leadership Research programme.

BSc, PhD

As the founding Executive Director of INEX, Dr Sidney Yee led the company through a series of key strategic partnerships, resulting in licensing collaborations for OvPlex™, and iGene™. She was also actively involved in the development of OvaCis™, an innovative Point of Care kit for the detection of Ovarian Cancer.

Dr Sidney Yee is currently the CEO of the Diagnostics Development Hub in Singapore, as well as the Senior Vice-President of A*STAR ETPL’s Investment & Spinoff Management division. She has over 20 years of experience in a career that spans research, investments, operations, management and entrepreneurship development. A serial entrepreneur, Dr Sidney Yee has been actively involved in technology innovations translation and start-ups. Dr Sidney Yee is currently a non-executive Director of INEX.


Mr. Sim Giok Lak has been a Director of INEX since March 2014. He is the Founder and Group MD and Chairman of Zicom Group Limited, and Australian listed company. Mr. Sim Chairs various medtech startups including Biobot Surgical Pte Ltd, Curiox Biosystems Pte Ltd, Histoindex Pte Ltd and Pellucid Networks Pte Ltd. Mr. Sim has considerable experience in public accounting, corporate development, financial and industrial management as well as international trade. He was a recipient of the Ernst and Young Entrepreneur Award (Industrial Products) in 2008 and was a member of the Entrepreneurship Review Committee Singapore 2013. Mr Sim is a Director of SPRING, Singapore, and a member of the Strategic Advisory Panel of the Diagnostic Development Hub.


Mr Sim is the Group Executive Director of Zicom Group Limited, Managing Director of iPtec Pte Ltd, and Chief Executive Officer of Zicom MedTacc Pte Ltd, a company focusing on investments and acceleration of early stage medical technologies companies. Both companies are supported by SPRING Singapore. His directorships in medtech companies include Biobot Surgical Pte Ltd, a spinoff from SingHealth and NTU that has developed a robotic platform for performing transperineal prostate biopsy; and Curiox Biosystems Pte Ltd, a spinoff from A*Star. Mr. Sim graduated with a Bachelor in Industrial and Operations Engineering (Magna Cum Laude) from the University of Michigan, Ann Arbor and a Masters in Financial Engineering from Columbia University, New York.



Management Group


Ms Vinita Choolani has been with INEX since September 2012 and is currently Vice President of Sales and Marketing. She was instrumental in the initial launch of iGene™ in Australia and Malaysia and is responsible for business development, distribution, communication and marketing strategy for INEX suite of products. Ms Choolani has over 20 years of business development and marketing experience, having worked at Fortune 500 companies across London, South Africa, Malaysia and Singapore. She earned her Bachelor of Arts & Social Sciences from the National University of Singapore.

PhD, MSc, B. Pharm

Dr. Francisco is an expert in genetics and molecular biology. As Head of Business Development, he identifies opportunities for innovation in the marketplace and connects them with emerging technologies in academic and research laboratories. His prior experience involved the conception, planning and development of molecular assays, from conceptual design to product launch. His areas of expertise are Next Generation Sequencing and Real Time PCR. He has extensive work experience in the Life Science industry across America, Europe and Asia. Dr. Francisco received his B. Pharm and MSc from University of Granada and a PhD in Biotechnology from University of Almeria, Spain in 2009.